Long-term Immune Durability After Vaccination With the Vesicular Stomatitis Virus-vectored Zaire Ebola Candidate Vaccine (VSV-EBOV): a Prospective Observational Cohort Study

Trial Profile

Long-term Immune Durability After Vaccination With the Vesicular Stomatitis Virus-vectored Zaire Ebola Candidate Vaccine (VSV-EBOV): a Prospective Observational Cohort Study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs RVSV-S-GP/VP40 vaccine (Primary)
  • Indications Ebola virus infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 08 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 18 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top